{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-25-031713","form_type":"8-K","ticker":"BTAI","cik":"0001720893","company_name":"BioXcel Therapeutics, Inc.","filed_at":"2025-04-03T23:59:59+00:00","discovered_at":"2026-05-14T18:02:49.464929+00:00","generated_at":"2026-05-23T22:41:34.885081+00:00","sec_items":["1.01","9.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"BioXcel Therapeutics enters ATM equity distribution agreement for up to $8.135M","bullets":["Entered Equity Distribution Agreement with Canaccord Genuity LLC on April 3, 2025.","May sell up to $8,135,000 of common stock via at-the-market offerings under existing shelf registration.","Canaccord receives up to 3.0% commission on gross proceeds; Company reimburses certain expenses.","Shares sold through Nasdaq or other trading market at prevailing prices with no minimum price."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-25-031713","json":"https://secwatch.observer/filing/0001104659-25-031713.json","markdown":"https://secwatch.observer/filing/0001104659-25-031713.md","text":"https://secwatch.observer/filing/0001104659-25-031713.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1720893/000110465925031713/0001104659-25-031713-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1720893/000110465925031713/tm2511361d2_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-23T22:41:34.885081+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}